Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02813837
Recruitment Status : Recruiting
First Posted : June 27, 2016
Last Update Posted : June 28, 2016
Sponsor:
Information provided by (Responsible Party):
Innovative Cellular Therapeutics Co., Ltd.

Brief Summary:
This single arm, open-label, multi-center clinical trial is studying CD19 targeted chimeric antigen receptor T cells therapy in treating patients with CD19 positive malignant B-cell derived leukemia and lymphoma that is relapsed (after stem cell transplantation or chemotherapy) or refractory to chemotherapy.

Condition or disease Intervention/treatment Phase
Leukemia, B-Cell Lymphoma, B-Cell Biological: CD19CART Not Applicable

Detailed Description:
This single arm, open-label, multi-center clinical trial is studying CD19 targeted chimeric antigen receptor T cells therapy in treating patients with CD19 positive malignant B-cell derived leukemia and lymphoma that is relapsed (after stem cell transplantation or chemotherapy) or refractory to chemotherapy. When patients enroll in this trial, autologous CD19CART cells were generated from the mononuclear cells of the patient's peripheral blood (PB). During the term of cell preparation of CD19CART cells, patients will receive a conditioning regimen. One day after completing conditioning regimen, the patient will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01)
Study Start Date : June 2015
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia Lymphoma

Arm Intervention/treatment
Experimental: single arm
Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
Biological: CD19CART
Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
Other Name: CD19-directed chimeric antigen receptor modified T cells




Primary Outcome Measures :
  1. Occurrence of study related adverse events [ Time Frame: up to 12 months ]

Secondary Outcome Measures :
  1. Anti-leukemia or lymphoma responses to CD19CART cell infusions [ Time Frame: up to 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients diagnosed as CD19 positive refractory and relapsed B cell hematologic malignancies included acute lymphoblastic leukemia (ALL),chronic lymphocytic leukemia(CLL),non-Hodgkin's lymphoma(NHL)
  • not eligible or appropriate for auto-HSCT or allo-HSCT or relapsed after hematopoietic stem cell transplant(HSCT)
  • At least one measurable lesion defined as one lesion larger than 1.5cm or two lesion more than 1.0cm(for patients with NHL )
  • Age ≤60 years
  • Eastern Cooperative Oncology Group(ECOG) Performance status 0 to 2, Expected survival > 6 months
  • Left Ventricular Ejection Fraction (LVEF) > 50%
  • no history of other malignancies;
  • no other serious diseases which conflict with the treatment in the present trial
  • All patients should consent to adopt efficient contraception methods during the treatment and after the treatment. The pregnant tests of women who are in child bearing period should be negative before the treatment.
  • patients should understand and are willing to participate in the trial. Inform consent form is supposed to obtained before treatment

Exclusion Criteria:

  • Diagnosis or classification undefined
  • Those with primary central nervous system lymphoma or testicular leukaemia or lymphoma
  • Patients with a known history or prior diagnosis of epilepsia or other disease affecting the central nervous system, or serious mental diseases;
  • Patients who have secondary leukaemia or lymphoma after chemotherapy or radiotherapy for other malignancies
  • Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy, concurrent use of immunosuppressant medications
  • Class III/IV cardiovascular disability according to the New York Heart Association Classification
  • Pregnant or lactating women(the safety of this therapy on unborn children is not known)
  • With active infection
  • Active hepatitis B, hepatitis C or syphilis infection
  • Patients use of systemic steroids within 2 weeks. Recent or current use of inhaled steroids is not exclusionary
  • Prior treatment with gene therapy product
  • Cluster of differentiation 3(CD3) positive cells<0.9x10^4/ml in peripheral blood (PB)
  • Organ function meeting following criteria: liver and renal function: alanine aminotransferase(ALT)/aspartate aminotransferase(AST) > 3 times the upper limit of normal, or bilirubin>2.0 mg/dl(34.2umol/L), or creatinine >2.5mg/dl(221.0umol/L) ; hematopoietic function:Neutrophil count<1.0x10^9/L,hemoglobin<80g/L,platelet <50x10^9/L(for patients with NHL )
  • Any uncontrolled active medical disorder that would preclude participation as outlined
  • HIV infection
  • The researchers considered unsuitable to participate in this clinical study.
  • Patients with poor compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02813837


Contacts
Layout table for location contacts
Contact: Lei Xiao, Ph.D +86-21-58950719

Locations
Layout table for location information
China
Innovative Cellular Therapeutics CO., LTD. Recruiting
Shanghai, China
Contact: Lei Xiao, Ph.D    +86-21-58950719      
Principal Investigator: Yu Hu, Ph.D         
Principal Investigator: He Huang, Ph.D         
Sponsors and Collaborators
Innovative Cellular Therapeutics Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Yu Hu, Ph.D Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology
Study Director: He Huang, Ph.D The First Affiliated Hospital of the College of Medicine, Zhejiang University
Layout table for additonal information
Responsible Party: Innovative Cellular Therapeutics Co., Ltd.
ClinicalTrials.gov Identifier: NCT02813837    
Other Study ID Numbers: SCT019-01
First Posted: June 27, 2016    Key Record Dates
Last Update Posted: June 28, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Innovative Cellular Therapeutics Co., Ltd.:
relapsed
refractory
CD19+
leukemia
lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Lymphoma, B-Cell
Leukemia, B-Cell
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia
Neoplasms by Site
Hematologic Diseases
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid